Cognition Therapeutics公司近日宣布，将延长其针对路易体痴呆症的在研药物Zervimesine（CT1812）的扩展使用计划。这一举措旨在为更多符合条件的患者提供早期获取该创新疗法的机会。
扩展使用计划的延续，体现了公司对满足未竟医疗需求的坚定承诺。Zervimesine作为一款靶向σ-2受体的新型小分子药物，通过调节突触功能，有望改善路易体痴呆患者的认知症状。
该计划允许尚未参与临床试验的患者，在特定条件下获得实验性治疗。研究人员将继续收集真实世界数据，为后续临床开发提供重要参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.